171 related articles for article (PubMed ID: 11829208)
1. Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia.
Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2001 Oct; 251(5):217-24. PubMed ID: 11829208
[TBL] [Abstract][Full Text] [Related]
2. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.
Freeman HL
Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S11-7. PubMed ID: 9218163
[TBL] [Abstract][Full Text] [Related]
3. Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation?
Blin O
Encephale; 2000 Oct; 26 Spec No 1():7-11. PubMed ID: 11294060
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.
Colonna L; Saleem P; Dondey-Nouvel L; Rein W
Int Clin Psychopharmacol; 2000 Jan; 15(1):13-22. PubMed ID: 10836281
[TBL] [Abstract][Full Text] [Related]
5. Amisulpride: progress and outcomes.
Lecrubier Y
Curr Med Res Opin; 2002; 18 Suppl 3():s18-22. PubMed ID: 12418608
[TBL] [Abstract][Full Text] [Related]
6. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group.
Danion JM; Rein W; Fleurot O
Am J Psychiatry; 1999 Apr; 156(4):610-6. PubMed ID: 10200742
[TBL] [Abstract][Full Text] [Related]
7. Treatment of positive and negative symptoms: pharmacologic approaches.
Boyer P; Lecrubier Y; Puech AJ
Mod Probl Pharmacopsychiatry; 1990; 24():152-74. PubMed ID: 1970852
[No Abstract] [Full Text] [Related]
8. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol.
Speller JC; Barnes TR; Curson DA; Pantelis C; Alberts JL
Br J Psychiatry; 1997 Dec; 171():564-8. PubMed ID: 9519098
[TBL] [Abstract][Full Text] [Related]
9. Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study.
Delcker A; Schoon ML; Oczkowski B; Gaertner HJ
Pharmacopsychiatry; 1990 May; 23(3):125-30. PubMed ID: 1973843
[TBL] [Abstract][Full Text] [Related]
10. Amisulpride: a review of its use in the management of schizophrenia.
Curran MP; Perry CM
Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on amisulpride in schizophrenia.
Curran MP; Perry CM
CNS Drugs; 2002; 16(3):207-11. PubMed ID: 11888341
[TBL] [Abstract][Full Text] [Related]
12. The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study.
Herrera-Estrella M; Apiquian R; Fresan A; Sanchez-Torres I
BMC Psychiatry; 2005 May; 5():22. PubMed ID: 15869707
[TBL] [Abstract][Full Text] [Related]
13. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.
Lecrubier Y; Quintin P; Bouhassira M; Perrin E; Lancrenon S
Acta Psychiatr Scand; 2006 Nov; 114(5):319-27. PubMed ID: 17022791
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].
Chabannes JP; Pelissolo A; Farah S; Gerard D
Encephale; 1998; 24(4):386-92. PubMed ID: 9809244
[TBL] [Abstract][Full Text] [Related]
15. Clinical advantages of amisulpride in the treatment of acute schizophrenia.
Burns T; Bale R
J Int Med Res; 2001; 29(6):451-66. PubMed ID: 11803729
[TBL] [Abstract][Full Text] [Related]
16. Amisulpride: a review of its use in the management of schizophrenia.
McKeage K; Plosker GL
CNS Drugs; 2004; 18(13):933-56. PubMed ID: 15521794
[TBL] [Abstract][Full Text] [Related]
17. Clinical update on amisulpride in deficit schizophrenia.
Rein W; Turjanski S
Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S19-27. PubMed ID: 9218164
[TBL] [Abstract][Full Text] [Related]
18. Safety of amisulpride (Solian): a review of 11 clinical studies.
Coulouvrat C; Dondey-Nouvel L
Int Clin Psychopharmacol; 1999 Jul; 14(4):209-18. PubMed ID: 10468313
[TBL] [Abstract][Full Text] [Related]
19. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.
Müller MJ; Wetzel H; Eich FX; Rein W; Puech A; Benkert O;
J Clin Psychopharmacol; 2002 Dec; 22(6):554-60. PubMed ID: 12454554
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients.
Riedel M; Eich FX; Möller HJ
Eur Psychiatry; 2009 Apr; 24(3):149-53. PubMed ID: 19070995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]